Li, Yiwen
Carpenito, Carmine
Wang, George
Surguladze, David
Forest, Amelie
Malabunga, Maria
Murphy, Mary
Zhang, Yiwei
Sonyi, Andreas
Chin, Darin
Burtrum, Douglas
Inigo, Ivan
Pennello, Anthony
Shen, Leyi
Malherbe, Laurent
Chen, Xinlei
Hall, Gerald
Haidar, Jaafar N.
Ludwig, Dale L.
Novosiadly, Ruslan D.
Kalos, Michael
Article History
Received: 14 December 2017
Accepted: 20 February 2018
First Online: 30 April 2018
Change Date: 4 June 2018
Change Type: Correction
Change Details: Unfortunately, after publication of this article [1], it was noticed that corrections to the legends of Figs. 1 and 2 were not correctly incorporated. The correct legends can be seen below.
Competing interests
: LY3300054 is an Eli Lilly and Company investigational drug currently in clinical testing. All authors are or have been employees and shareholders of Eli Lilly and Company.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.